Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015695 (fatty liver)
 13,941 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of dietary orotic acid on the levels of liver and blood NAD in young rats was investigated. Weanling rats were fed on a nicotinic acid-free, 20% casein diet containing 0% (control diet) or 1% orotic acid (test diet) for 32 days. Retardation of growth, development of fatty liver and enlargement of liver were observed in the test group in comparison with the control group. In the test group, the amounts of quinolinic acid, niacin, NAD and N1-methylnicotinamide, and the activities of quinolinate phosphoribosyltransferase, nicotinamide mononucleotide adenylyltransferase, nicotinamide methyltransferase and NAD synthetase expressed in terms of g liver were significantly decreased compared to the control group. When these values were expressed in terms of whole liver, a significant difference was observed in the content of NAD and the activity of NAD synthetase between the control and the test groups. The activity of aminocarboxymuconate-semialdehyde decarboxylase expressed in terms of whole liver was about 2-fold higher in the test group than in the control group, but was not significantly different. The levels of NAD in blood as well as in liver were significantly lower in the test group than in the control group. Urinary excretions of quinolinic acid, niacin and N1-methylnicotinamide were also reduced in the test group. These results are discussed in the light of the reported effect of orotic acid in lowering the level of ATP in liver.
 ...
PMID:Effect of dietary orotic acid on the levels of liver and blood NAD in rats. 293 93

MAF1 is a global repressor of RNA polymerase III transcription that regulates the expression of highly abundant noncoding RNAs in response to nutrient availability and cellular stress. Thus, MAF1 function is thought to be important for metabolic economy. Here we show that a whole-body knockout of Maf1 in mice confers resistance to diet-induced obesity and nonalcoholic fatty liver disease by reducing food intake and increasing metabolic inefficiency. Energy expenditure in Maf1(-/-) mice is increased by several mechanisms. Precursor tRNA synthesis was increased in multiple tissues without significant effects on mature tRNA levels, implying increased turnover in a futile tRNA cycle. Elevated futile cycling of hepatic lipids was also observed. Metabolite profiling of the liver and skeletal muscle revealed elevated levels of many amino acids and spermidine, which links the induction of autophagy in Maf1(-/-) mice with their extended life span. The increase in spermidine was accompanied by reduced levels of nicotinamide N-methyltransferase, which promotes polyamine synthesis, enables nicotinamide salvage to regenerate NAD(+), and is associated with obesity resistance. Consistent with this, NAD(+) levels were increased in muscle. The importance of MAF1 for metabolic economy reveals the potential for MAF1 modulators to protect against obesity and its harmful consequences.
 ...
PMID:Loss of the RNA polymerase III repressor MAF1 confers obesity resistance. 2593 5

Abnormal hepatic insulin signaling is a cause or consequence of hepatic steatosis. DPP-4 inhibitors might be protective against fatty liver. We previously reported that the systemic inhibition of insulin receptor (IR) and IGF-1 receptor (IGF1R) by the administration of OSI-906 (linsitinib), a dual IR/IGF1R inhibitor, induced glucose intolerance, hepatic steatosis, and lipoatrophy in mice. In the present study, we investigated the effects of a DPP-4 inhibitor, linagliptin, on hepatic steatosis in OSI-906-treated mice. Unlike high-fat diet-induced hepatic steatosis, OSI-906-induced hepatic steatosis is not characterized by elevations in inflammatory responses or oxidative stress levels. Linagliptin improved OSI-906-induced hepatic steatosis via an insulin-signaling-independent pathway, without altering glucose levels, free fatty acid levels, gluconeogenic gene expressions in the liver, or visceral fat atrophy. Hepatic quantitative proteomic and phosphoproteomic analyses revealed that perilipin-2 (PLIN2), major urinary protein 20 (MUP20), cytochrome P450 2b10 (CYP2B10), and nicotinamide N-methyltransferase (NNMT) are possibly involved in the process of the amelioration of hepatic steatosis by linagliptin. Thus, linagliptin improved hepatic steatosis induced by IR and IGF1R inhibition via a previously unknown mechanism that did not involve gluconeogenesis, lipogenesis, or inflammation, suggesting the non-canonical actions of DPP-4 inhibitors in the treatment of hepatic steatosis under insulin-resistant conditions.
 ...
PMID:Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor. 3310 4